Key Takeaways
- ARK Invest purchased approximately 281,000 shares of CRSP valued at roughly $14.82M following a 10% decline
- CRISPR Therapeutics triggered the selloff by revealing a $350M private placement
- CRSP represents ARK’s second-biggest position across all ETFs, totaling approximately $500M in exposure
- ARK reduced holdings in 10x Genomics (TXG) and Teradyne (TER) during portfolio rebalancing
- Both Seeking Alpha Quant ratings and Wall Street consensus assign CRSP a Buy rating
Shares of CRISPR Therapeutics (CRSP) tumbled approximately 10% following the biotechnology company’s disclosure of a $350M private placement. Cathie Wood’s ARK Invest responded by accumulating shares during the pullback.
According to ARK’s daily trading disclosure dated March 11, 2026, the investment firm acquired roughly 281,000 shares of CRSP across its exchange-traded funds, representing approximately $14.82M in value.
This purchase represents a continuation of ARK’s bullish stance. During the fourth quarter of 2025, Wood had already expanded ARK’s CRSP stake by 7.5%, accumulating approximately 735,000 shares. The recent acquisition extends this accumulation pattern.
Across ARK’s combined ETF portfolio, CRSP now stands as the second-largest position, accounting for 4.49% of total portfolio weight with approximately $500M in aggregate exposure. This constitutes a substantial wager on a company that has yet to generate meaningful revenue.
Private Placement Triggers Investor Concern
The double-digit percentage decline occurred after CRISPR Therapeutics unveiled plans for a $350M private placement. Such capital raises typically dilute existing shareholders, creating near-term downward pressure on share prices.
The fundraising initiative shouldn’t come as a surprise. With zero revenue and negative operating margins, CRISPR Therapeutics must continually raise capital to advance its clinical pipeline.
Despite the cash burn, the company maintains a robust financial position — boasting a current ratio of 13.32 and a minimal debt-to-equity ratio of 0.11, indicating substantial liquidity coupled with minimal leverage.
This solid balance sheet likely provided ARK with confidence to accumulate shares during the weakness.
CRISPR’s Clinical Pipeline and Commercialization
CRISPR Therapeutics’ initial commercialized therapy, Casgevy, resulted from a partnership with Vertex Pharmaceuticals and addresses sickle-cell disease and transfusion-dependent beta-thalassemia.
The company’s pipeline extends beyond Casgevy into multiple therapeutic areas including immuno-oncology, cardiovascular disorders, and stem cell-based treatments for Type 1 diabetes.
According to recent filings, the company carries a market capitalization of approximately $5.07 billion.
Corporate insider transactions have skewed heavily toward selling recently — five separate insider sales over the previous three months totaling 163,751 shares, with zero insider purchases recorded.
Portfolio Adjustments Across ARK’s Holdings
While accumulating CRSP shares, ARK simultaneously reduced exposure elsewhere. The firm disposed of 78,412 shares of 10x Genomics (TXG) valued at approximately $1.60M and sold 21,505 shares of Teradyne (TER) worth $6.47M.
These sales seem to reflect standard portfolio rebalancing activities within ARK’s actively managed ETF structure rather than bearish sentiment toward those particular companies.
From an analyst perspective, CRSP maintains a Buy rating from both Seeking Alpha’s Quant scoring system and the Wall Street analyst community. The Quant methodology assigns particularly strong scores to growth potential and momentum factors.
A Seeking Alpha analyst highlighted Casgevy’s market launch and the company’s substantial cash position as notable strengths, while acknowledging the inherent uncertainties associated with pre-revenue biotechnology investments.
However, GuruFocus’s GF Value metric suggests CRSP trades at a significant premium, calculating a fair value of $16.13, which contrasts with the optimistic Wall Street outlook.
CRSP finished the trading session down approximately 10.17% on the day the private placement was announced.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
